Isolated limb perfusion with high-dose melphalan and TNF-alpha has a high response rate and results in good survival outcomes in patients with locally advanced angiosarcoma, according to results of a new study.
Adding trastuzumab to anthracycline and taxane-based chemotherapy does not result in worsening of long-term cardiac outcomes in patients with node-positive, HER2-positive early breast cancer, according to a new study.
The immune checkpoint inhibitor pembrolizumab demonstrated antitumor activity in a small trial of patients with advanced cervical cancer. The agent had a similar toxicity profile to that seen in other malignancies.
Men with Medicaid are more likely to present with metastatic prostate cancer than men presenting with prostate cancer who have private insurance, according to a new study. There are racial disparities in terms of prostate cancer outcomes among those privately insured, but not among Medicaid recipients.
Achievement of event-free survival at 24 months is highly predictive of overall survival in patients with peripheral T-cell lymphomas, according to a new study.
Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
A novel risk classification scheme based on expression of 36 micro-RNA samples was able to identify pediatric patients with acute myeloid leukemia at high or low risk of experiencing treatment failure, according to a new analysis.
An analysis of treatment patterns found that patients with advanced urinary tract cancer who are eligible for cisplatin-based chemotherapy fare better when they do receive such regimens than when they do not, highlighting the importance of following published treatment criteria.
A new risk model was effective at identifying individuals subsequently diagnosed with early and potentially curable lung cancer.
In patients with chronic myeloid leukemia treated with bosutinib who were resistant or intolerant to previous tyrosine kinase inhibitors, health-related quality of life was well maintained over the long term.